Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide.
Tan DHS, Antinori A, Eu B, Galindo Puerto MJ, Kinder C, Sweet D, Dam CNV, Sutton K, Sutherland-Phillips D, Berni A, Zhang F, Urbaityte R, Baugh B, Spreen W, Wyk JV, Garges HP, Patel P, Batterham R, D'amico R.
Tan DHS, et al. Among authors: sutton k.
J Acquir Immune Defic Syndr. 2024 Dec 16. doi: 10.1097/QAI.0000000000003584. Online ahead of print.
J Acquir Immune Defic Syndr. 2024.
PMID: 39676239